Description     Claims     Drawing  

US61806497   [0002] 
US7344710B   [0021]  [0207] 
EP1236471A2   [0053] 
US4599331A   [0053] 
US4771042A   [0053] 
WO198702672A   [0053] 
WO1990015816A1   [0053] 
US6905480B   [0107] 
US7331947B   [0107] 

Information needed to conduct first-in human oncology trials in the United States: a view from a former FDA medical reviewer   [0027] 
CHEMICAL ABSTRACTS   [0044] 
CHEMICAL ABSTRACTS   [0044] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0066] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0072] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
CHEMICAL ABSTRACTS   [0078] 
The Science and Practice of Pharmacy   [0111]  [0112] 
Bacteriolytic therapy can generate a potent immune response against experimental tumors   [0207] 
V. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme   [0207] 
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy   [0207] 
The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT   [0207] 
The Number of Colonies Allowable on Satisfactory Agar Plates   [0207] 
Clostridial oncolysis in man   [0207] 
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors   [0207] 
Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-Microtubule Agents   [0207] 
Combination bacteriolytic therapy for the treatment of experimental tumors   [0207] 
Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs   [0207] 
Pharmacologic and toxicologic evaluation of C. novyi-NT spores   [0207] 
Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products   [0207] 
Solid Tumors: Facts, Challenges and Solutions   [0207] 
Can engineered bacteria help control cancer?   [0207] 
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma   [0207] 
Exomic Analysis of myxoid liposarcomas, synovial sarcomas and osteosarcomas   [0207] 
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers   [0207] 
Clostridium Strain M55 and its effect on Malignant Tumors   [0207] 
Onkolyse durch Clostridien   [0207] 
Translation of new cancer treatments from pet dogs to humans   [0207] 
Effect of histolyticus infection and toxin on transplantable mouse tumors   [0207] 
Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs   [0207] 
Histologic Grading of Canine Mast Cell Tumor: Is 2 Better Than 3?   [0207] 
Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation   [0207] 
Spontaneously occurring tumors of companion animals as models for human cancer   [0207] 
Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0   [0207] 
Cancer genome landscapes   [0207]